An update from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
On April 15, 2025, Inspira Technologies announced its first revenue generation from the deployment of its FDA-cleared INSPIRA ART100 systems at a leading U.S. healthcare facility. This marks a significant milestone in the company’s strategy to expand its presence in the U.S. healthcare market. The company plans to install additional systems at another academic medical center, reinforcing its commitment to advancing its life-support systems and expanding its clinical footprint. This achievement validates Inspira’s innovative technology and its ability to collaborate with top-tier medical institutions.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
Inspira Technologies Oxy BHN is currently facing significant financial and operational challenges. The lack of revenue generation and continued losses are major concerns. Technical analysis reflects a bearish outlook with downward momentum and weak price trends. The valuation does not provide enough incentive for investment given the underlying risks.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a company pioneering in innovative life-support and diagnostic technologies. The company focuses on developing systems like the INSPIRA ART100, which is FDA-cleared for cardiopulmonary bypass procedures, and the INSPIRA ART500, which aims to revolutionize the mechanical ventilation market by providing alternatives for respiratory failure patients. Inspira Technologies is also working on the HYLA blood sensor technology for real-time blood monitoring.
YTD Price Performance: -41.52%
Average Trading Volume: 725,125
Technical Sentiment Signal: Buy
Current Market Cap: $15.74M
Find detailed analytics on IINN stock on TipRanks’ Stock Analysis page.